AzurRx BioPharma Inc. and Lion Group Holding Ltd. in race to be NASDAQ top bottom performer of the day
The National Association of Securities Dealers Automated Quotations (NASDAQ) Composite Index opened at 13,414.32 on 1st April 2021. Till 1 PM the highest it touched was 13,487.08 and lowest 13,404.18
Top 5 Bottom Performers Till 1 PM:
AzurRx BioPharma Inc. (Change -29.10% Priced at $0.9)
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.
Lion Group Holding Ltd. ADR (Change -19.01% Priced at $3.5)
Lion Group Holding Ltd is an investment holding company principally engaged in the provision of financial services. The Company’s businesses include contracts for difference (CFD) trading services, insurance brokerage services, futures brokerage services, securities brokerage services, asset management services and others.
LAVA Therapeutics N.V. (Change -14.75% Priced at $12.9)
Lava Therapeutics BV is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Wah Fu Education Group Ltd. (Change -16.32% Priced at $10.4)
Wah Fu Education Group Ltd. is a holding company, which engages in the provision of online exam preparation services and related technology solutions, and production of online training course materials. It operates through the Online Education Cloud Service (B2B2C) and Online Training Service (B2C). The B2B2C segment comprises online education platforms to institutions, such as universities and training institutions, and online course development service companies. The B2C segment provides online training and examination preparation services directly to students for a fee. The company was founded on July 23, 2012 and is headquartered in Beijing, China.
Ikena Oncology Inc. (Change -15.75% Priced at $23.8)
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
